NASDAQ:ALLO - Allogene Therapeutics Price Target & Analyst Ratings Sign in or create an account to add this stock to your watchlist. Get Started $25.79 -0.16 (-0.62 %) (As of 04/23/2019 01:53 AM ET)Previous Close$25.95Today's Range$25.51 - $26.1252-Week Range$21.67 - $35.55Volume255,566 shsAverage Volume407,902 shsMarket Capitalization$3.13 billionP/E RatioN/ADividend YieldN/ABetaN/A ProfileDiscussionAnalyst RatingsChartEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Analyst Ratings Allogene Therapeutics (NASDAQ:ALLO) Price Target and Consensus Rating (How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.7 Wall Street analysts have issued ratings and price targets for Allogene Therapeutics in the last 12 months. Their average twelve-month price target is $38.20, suggesting that the stock has a possible upside of 48.12%. The high price target for ALLO is $50.00 and the low price target for ALLO is $29.00. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus rating of "Buy."Today30 Days Ago90 Days Ago180 Days AgoConsensus Rating: BuyBuyBuyN/AConsensus Rating Score: 2.862.832.75N/ARatings Breakdown: 0 Sell Rating(s)1 Hold Rating(s)6 Buy Rating(s)0 Strong Buy Rating(s)0 Sell Rating(s)1 Hold Rating(s)5 Buy Rating(s)0 Strong Buy Rating(s)0 Sell Rating(s)1 Hold Rating(s)3 Buy Rating(s)0 Strong Buy Rating(s)0 Sell Rating(s)0 Hold Rating(s)0 Buy Rating(s)0 Strong Buy Rating(s)Consensus Price Target: $38.20$35.25$33.6667N/APrice Target Upside: 48.12% upside32.87% upside24.69% upsideN/AAllogene Therapeutics (NASDAQ:ALLO) Consensus Price Target History Allogene Therapeutics (NASDAQ:ALLO) Analyst Ratings History Show: Only the Most Recent Rating From Each Brokerage All Ratings For This Stock DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails4/15/2019William BlairReiterated RatingBuyLow3/29/2019Piper Jaffray CompaniesInitiated CoverageOverweight ➝ Overweight$50.00High3/14/2019Raymond JamesInitiated CoverageOutperform ➝ Outperform$40.00Medium3/11/2019JPMorgan Chase & Co.Reiterated RatingHold$29.00Medium3/8/2019CowenReiterated RatingBuyLow11/5/2018Jefferies Financial GroupInitiated CoverageBuy ➝ Buy$31.00High11/5/2018Goldman Sachs GroupInitiated CoverageBuy ➝ Buy$41.00High(Data available from 4/23/2017 forward) This page was last updated on 4/23/2019 by MarketBeat.com StaffFeatured Article: What are benefits of a growth and income fund?